These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 18667446)
1. Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. Cao L; Petrusca DN; Satpathy M; Nakshatri H; Petrache I; Matei D Carcinogenesis; 2008 Oct; 29(10):1893-900. PubMed ID: 18667446 [TBL] [Abstract][Full Text] [Related]
2. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells. Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684 [TBL] [Abstract][Full Text] [Related]
3. Alkaloids from Stephania venosa as Chemo-Sensitizers in SKOV3 Ovarian Cancer Cells via Akt/NF-κB Signaling. Mon MT; Yodkeeree S; Punfa W; Pompimon W; Limtrakul P Chem Pharm Bull (Tokyo); 2018; 66(2):162-169. PubMed ID: 29386467 [TBL] [Abstract][Full Text] [Related]
4. p62/SQSTM1 as an oncotarget mediates cisplatin resistance through activating RIP1-NF-κB pathway in human ovarian cancer cells. Yan XY; Zhang Y; Zhang JJ; Zhang LC; Liu YN; Wu Y; Xue YN; Lu SY; Su J; Sun LK Cancer Sci; 2017 Jul; 108(7):1405-1413. PubMed ID: 28498503 [TBL] [Abstract][Full Text] [Related]
6. Association of expression of XIAP-associated factor 1 (XAF1) with clinicopathologic factors, overall survival, microvessel density and cisplatin-resistance in ovarian cancer. Wang Y; Mao H; Hao Q; Wang Y; Yang Y; Shen L; Huang S; Liu P Regul Pept; 2012 Oct; 178(1-3):36-42. PubMed ID: 22759793 [TBL] [Abstract][Full Text] [Related]
7. Tissue transglutaminase constitutively activates HIF-1α promoter and nuclear factor-κB via a non-canonical pathway. Kumar S; Mehta K PLoS One; 2012; 7(11):e49321. PubMed ID: 23185316 [TBL] [Abstract][Full Text] [Related]
8. Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer. Miow QH; Tan TZ; Ye J; Lau JA; Yokomizo T; Thiery JP; Mori S Oncogene; 2015 Apr; 34(15):1899-907. PubMed ID: 24858042 [TBL] [Abstract][Full Text] [Related]
9. FSTL1 increases cisplatin sensitivity in epithelial ovarian cancer cells by inhibition of NF-κB pathway. Liu YK; Jia YJ; Liu SH; Ma J Cancer Chemother Pharmacol; 2021 Mar; 87(3):405-414. PubMed ID: 33392640 [TBL] [Abstract][Full Text] [Related]
10. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Asselin E; Mills GB; Tsang BK Cancer Res; 2001 Mar; 61(5):1862-8. PubMed ID: 11280739 [TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway. Zhang C; Wang M; Shi C; Shi F; Pei C Biosci Trends; 2018 Jul; 12(3):309-316. PubMed ID: 29952351 [TBL] [Abstract][Full Text] [Related]
12. [Effect of MTRR gene on apoptosis and autophagy pathways in multiresistant epithelial ovarian cancer]. Chen J; Wang Q; Zhang W; Li L Zhonghua Fu Chan Ke Za Zhi; 2016 Apr; 51(4):285-92. PubMed ID: 27116987 [TBL] [Abstract][Full Text] [Related]
13. The inhibitory effect of doxycycline on cisplatin-sensitive and -resistant epithelial ovarian cancer. Wu W; Yu LH; Ma B; Xu MJ PLoS One; 2014; 9(3):e89841. PubMed ID: 24598933 [TBL] [Abstract][Full Text] [Related]
14. Caveolin-1 mediates chemoresistance in cisplatin-resistant ovarian cancer cells by targeting apoptosis through the Notch-1/Akt/NF-κB pathway. Zou W; Ma X; Hua W; Chen B; Cai G Oncol Rep; 2015 Dec; 34(6):3256-63. PubMed ID: 26503358 [TBL] [Abstract][Full Text] [Related]
15. BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells. Chock KL; Allison JM; Shimizu Y; ElShamy WM Cancer Res; 2010 Nov; 70(21):8782-91. PubMed ID: 20940403 [TBL] [Abstract][Full Text] [Related]
16. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway. Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137 [TBL] [Abstract][Full Text] [Related]
17. Phosphorylation of transglutaminase 2 (TG2) at serine-216 has a role in TG2 mediated activation of nuclear factor-kappa B and in the downregulation of PTEN. Wang Y; Ande SR; Mishra S BMC Cancer; 2012 Jul; 12():277. PubMed ID: 22759359 [TBL] [Abstract][Full Text] [Related]
18. Knockdown of Eag1 Expression by RNA Interference Increases Chemosensitivity to Cisplatin in Ovarian Cancer Cells. Hui C; Lan Z; Yue-li L; Li-lin H; Li-lin H Reprod Sci; 2015 Dec; 22(12):1618-26. PubMed ID: 26079730 [TBL] [Abstract][Full Text] [Related]
19. PDCD6 additively cooperates with anti-cancer drugs through activation of NF-κB pathways. Park SH; Lee JH; Lee GB; Byun HJ; Kim BR; Park CY; Kim HB; Rho SB Cell Signal; 2012 Mar; 24(3):726-33. PubMed ID: 22142513 [TBL] [Abstract][Full Text] [Related]
20. LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells. Gao Y; Shan N; Zhao C; Wang Y; Xu F; Li J; Yu X; Gao L; Yi Z Int J Clin Exp Pathol; 2015; 8(5):4923-32. PubMed ID: 26191185 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]